[quote SexTrainGlue]The list you have linked is the CEV (priority 4 list)
The 16-64 (priority 6) list in in table 3 of this guidance (sorry that this is provisional version, but I don't think anything changed other than age dropping fro 18)
assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/941450/Greenbook_chapter_14a_v2.pdf[/quote]
Ah - thanks for the correct link. Here's Table 3 for those interested:
Table 3 Clinical risk groups 16 years of age and over who should receive COVID-19 immunisation.
Chronic respiratory disease
Individuals with a severe lung condition, including those with asthma that
requires continuous or repeated use of systemic steroids or with previous
exacerbations requiring hospital admission, and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema;
bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and
bronchopulmonary dysplasia (BPD).
Chronic heart disease and vascular disease
Congenital heart disease, hypertension with cardiac complications, chronic
heart failure, individuals requiring regular medication and/or follow-up for
ischaemic heart disease. This includes individuals with atrial fibrillation,
peripheral vascular disease or a history of venous thromboembolism.
Chronic kidney disease
Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic
syndrome, kidney transplantation.
Chronic liver disease Cirrhosis, biliary atresia, chronic hepatitis.
Chronic neurological disease
Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological disease (e.g. polio syndrome sufferers). This includes individuals with cerebral palsy, severe or profound learning disabilities, Down’s Syndrome, multiple sclerosis,
epilepsy, dementia, Parkinson’s disease, motor neurone disease and related
or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability.
Diabetes mellitus Any diabetes, including diet-controlled diabetes.
Immunosuppression
Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients
undergoing radical radiotherapy, solid organtransplant recipients, bone
marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).
Individuals who are receiving immunosuppressive or immunomodulating
biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as
cyclophosphamide and mycophenolate mofetil.
Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day (any age).
Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long term
immunosuppressive treatments.
Some immunosuppressed patients may have a suboptimal immunological response to the vaccine.
Asplenia or dysfunction of the spleen
This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome.
Morbid obesity Adults with a Body Mass Index ≥40 kg/m².
Severe mental illness Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment.
Adult carers
Those who are in receipt of a carer’s allowance, or those who are the main carer of an elderly or disabled person whose welfare may be at risk if the
carer falls ill.
Younger adults in long-stay nursing and residential care settings
Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above.
Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended.
Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents should not be excluded from vaccination programmes (see priority 1 above).